

Bamboo Technology Highlights Clinical Foundation of HereHear Ahead of INNOVEX 2026

Voice-AI mental wellness platform supported by peer-reviewed PLOS ONE publication, JETRO-funded therapeutic trial in Japan, and active randomized controlled trial at Taipei Veterans General Hospital

TAIPEI, Taiwan — May 14, 2026 — Ahead of its debut at INNOVEX 2026, Bamboo Technology, Ltd. (竹謙科技) today summarized the clinical evidence base underlying **HereHear**, its voice-native AI mental wellness platform. The evidence spans three independent studies across Taiwan and Japan, covering both technology validation and therapeutic outcome.

“Clinical evidence in consumer mental wellness AI is rare, and getting more important. We invested in the harder, slower path — peer-reviewed publication, government-funded therapeutic trial, an active RCT — because that is what gives us standing in international markets.”

— Lynia Huang, Founder and CEO, Bamboo Technology, Ltd.

I. Peer-Reviewed Publication — PLOS ONE

A 2025 study published in *PLOS ONE* (Huang & Chang; DOI: 10.1371/journal.pone.0339365), conducted independently by a Taipei Medical University team, validated HereHear’s voice-emotion AI engine against four internationally standardized clinical scales — including the Beck Depression Inventory-II and the Perceived Stress Scale — with 349 clinical nurses at TMU Shuang Ho Hospital. All four AI emotion outputs showed statistically significant correlation with their corresponding clinical measures ($r = .42$ to $.47$, all $p < .001$), establishing the technology validity of the voice-emotion engine.

II. Government-Funded Therapeutic Trial — Xiberlinc / JETRO

A Japan–Taiwan joint initiative led by Xiberlinc Inc. (Japan) with Bamboo Technology as the technology collaboration partner, funded under the JETRO Foreign Direct Investment Promotion Subsidy Program (2025), found clinically meaningful effect sizes after an 8-week HereHear intervention with 48 participants screened for moderate-or-higher depressive tendencies (suicidal ideation excluded): Cohen’s $d = 0.62$ for PHQ-9 depression ($p < .001$), 0.61 for GAD-7 anxiety ($p = .003$), and 0.73 for body-awareness measured by the Body Perception Questionnaire ($p = .001$). The study collected multimodal data including EEG and voice biomarkers; integrated EEG analysis is ongoing. Findings were reported in Xiberlinc’s January 2026 JETRO subsidy completion report.

III. Active Randomized Controlled Trial — Taipei Veterans General Hospital

An IRB-approved randomized controlled trial currently in progress at Taipei Veterans General Hospital (N = 50) is evaluating HereHear as an adjunct intervention for cancer patients facing depression, anxiety, and sleep disturbance. The 12-week intervention plus 24-week follow-up design tests both immediate and durable effects. Full peer-reviewed results are targeted for publication in 2026–2027.

Bamboo Technology will discuss specific partnership opportunities — across enterprise EAP, technology licensing, and public health collaboration — when INNOVEX 2026 opens later this month.

#

About Bamboo Technology, Ltd. (竹謙科技)

Founded in 2018, Bamboo Technology, Ltd. is a Taiwan-headquartered AI mental wellness company on a mission to make emotional support as accessible as a phone call to a friend who is awake at 2 a.m. Its flagship product, HereHear, combines a clinically validated voice-emotion AI engine with a 3D AI companion experience available in Mandarin, English, and Japanese, designed to provide immediate, anonymous emotional support that complements — rather than replaces — professional mental health care. Learn more at www.bamboodd.com.

MEDIA CONTACT

Serena Cheng

Sales Manager, Bamboo Technology, Ltd. (竹謙科技)
serena.cheng@bamboodd.com
www.bamboodd.com